Table 2.
Baseline | Bipolar disorder, follow-up | |||||
---|---|---|---|---|---|---|
Healthy controls (n = 31) | Bipolar disorder (n = 27) | p-value | Baseline (n = 13) | Follow-up (n = 13) | p-value | |
Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |||
ALA | ||||||
E | 19.89 (25.64) | 18.86 (12.81) | 0.85 | 18.48 (17.30) | 25.45 (15.42) | 0.18 |
UE | 2.10 (2.80) | 1.40 (1.77) | 0.27 | 0.88 (1.06) | 2.28 (1.72) | 0.02 |
DHA | ||||||
E | 220.93 (93.79) | 221.37 (83.10) | 0.99 | 227.46 (84.10) | 177.71 (161.19) | 0.28 |
UE | 1.07 (0.64) | 1.04 (1.04) | 0.89 | 0.73 (0.38) | 0.55 (0.26) | 0.11 |
EPA | ||||||
E | 8.91 (6.94) | 13.91 (13.39) | 0.07 | 14.62 (18.98) | 12.68 (6.86) | 0.75 |
UE | 0.32 (0.18) | 0.20 (0.08) | 0.002 | 0.21 (0.06) | 0.31 (0.26) | 0.16 |
UE:E | ||||||
ALA | 0.14 (0.13) | 0.08 (0.10) | 0.05 | 0.08 (0.13) | 0.12 (0.10) | 0.27 |
DHA | 0.006 (0.005) | 0.005 (0.003) | 0.34 | 0.004 (0.003) | 0.005 (0.003) | 0.32 |
EPA | 0.05 (0.03) | 0.02 (0.01) | 9 × 10−5 | 0.02 (0.02) | 0.04 (0.07) | 0.24 |
DHA:ALA | ||||||
E | 18.20 (11.34) | 14.27 (6.05) | 0.10 | 16.15 (6.05) | 7.44 (5.36) | 0.001 |
UE | 0.92 (0.86) | 1.13 (0.77) | 0.33 | 1.12 (0.43) | 0.31 (0.17) | 4 × 10−5 |
EPA:ALA | ||||||
E | 0.61 (0.23) | 0.71 (0.18) | 0.07 | 0.72 (0.19) | 0.54 (0.20) | 0.06 |
UE | 0.28 (0.18) | 0.26 (0.17) | 0.78 | 0.36 (0.17) | 0.19 (0.16) | 0.002 |
EPA:DHA | ||||||
E | 0.05 (0.03) | 0.08 (0.12) | 0.13 | 0.09 (0.17) | 0.10 (0.07) | 0.86 |
UE | 0.39 (0.29) | 0.30 (0.21) | 0.18 | 0.37 (0.24) | 0.58 (0.29) | 0.03 |
SD = standard deviation; E = esterified; UE = unesterified; ALA = alpha-linolenic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid.